1-Year Outcomes of Lung Transplantation for Coronavirus Disease 2019–Associated End-Stage Lung Disease in the United States
Clinical Infectious Diseases · 2023
DOI: 10.1093/cid/ciad072 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Kenji Okumura und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Westchester Medical Center/New York Medical College, New York, New York, USA. Hauptthemen laut MEDLINE: Heart Transplantation, COVID-19, Lung Transplantation, Lung Diseases. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Background
Lung transplantation can provide quality of life and survival benefits for patients with coronavirus disease 2019 (COVID-19)–associated end-stage lung disease. Characteristics and outcomes of these lung transplant recipients are limited to mostly single-center experiences or provide a short-term follow-up.
Methods
Characteristics of deceased donors and adult lung transplant recipients for COVID-19–associated end-stage lung disease between August-2020 and June-2022 were analyzed using deidentified United Network for Organ Sharing database. Post-transplant patient survival of COVID-19 recipients was analyzed and compared with non–COVID-19 recipients. Secondary outcomes were length of hospitalization, post-transplant complications, and rates of organ rejection.
Results
During the study period, 400 lung transplants for COVID-associated end-stage lung disease comprised 8.7% of all lung transplants performed in United States. In the COVID-19 group, Hispanic males received lung transplants at significantly higher rates. The COVID-19 group was younger and had greater need for intensive care unit stay, mechanical ventilation, hemodialysis, extracorporeal membrane oxygenation support, and receipt of antibiotics pre-lung transplant. They had higher lung allocation score, with a shorter wait-list time and received more double lung transplants compared with non–COVID-19 recipients. Post-transplant, the COVID-19 cohort had longer hospital stays, with similar 1-year patient survival (COVID, 86.6% vs non–COVID, 86.3%). Post-transplant, COVID-19–associated deaths were 9.2% of all deaths among lung transplant recipients.
Conclusions
Lung transplantation offers a effective option for carefully selected patients with end-stage lung disease from prior COVID-19, with short-term and long-term outcomes similar to those for lung transplant recipients of non–COVID-19 etiology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Westchester Medical Center/New York Medical College, New York, New York, USA.
- Center for Advanced Cardiopulmonary Therapies and Transplantation, McGovern Medical School, UT Health Houston, Houston, Texas, USA.
- Department of Pulmonary Allergy and Critical Care, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Transplant Infectious Diseases, Department of Medicine & Surgery, Westchester Medical Center/New York Medical College, New York, New York, USA.
ORCID-Profile: Kenji Okumura, Soma Jyothula, Thomas Kaleekal, Abhay Dhand
Zitieren
APA
Okumura, K., Jyothula, S., Kaleekal, T., & Dhand, A. (2023). 1-Year Outcomes of Lung Transplantation for Coronavirus Disease 2019–Associated End-Stage Lung Disease in the United States. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad072
Vancouver
Okumura K, Jyothula S, Kaleekal T, Dhand A. 1-Year Outcomes of Lung Transplantation for Coronavirus Disease 2019–Associated End-Stage Lung Disease in the United States. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciad072
BibTeX
@article{Okumura2023,
author = {Okumura, Kenji and Jyothula, Soma and Kaleekal, Thomas and Dhand, Abhay},
title = {1-Year Outcomes of Lung Transplantation for Coronavirus Disease 2019–Associated End-Stage Lung Disease in the United States},
journal = {Clinical Infectious Diseases},
year = {2023},
doi = {10.1093/cid/ciad072}
}
EUVIMED